Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q70Z53
UPID:
F10C1_HUMAN
Alternative names:
-
Alternative UPACC:
Q70Z53; C9JCR4; C9JCR5; C9JMY4; Q70Z49; Q70Z50; Q70Z51; Q70Z52; Q8N293; Q8WVH5; Q96JQ8
Background:
Protein FRA10AC1 plays a crucial role in the cellular process, potentially involved in pre-mRNA splicing. This protein's intricate involvement in cellular mechanisms underscores its importance in maintaining cellular integrity and function.
Therapeutic significance:
Linked to a neurodevelopmental disorder characterized by developmental delay, intellectual disability, and craniofacial dysmorphism, Protein FRA10AC1's study offers insights into therapeutic interventions. Understanding the role of Protein FRA10AC1 could open doors to potential therapeutic strategies.